Research
Hormonal
There is a greater emphasis on adjunct pharmacotherapy in the updated guideline, particularly with GLP-1-based agents for weight reduction and improvement of comorbidities.
Healthcare providers should integrate GLP-1-based pharmacotherapy into obesity management strategies.
StrongSupportsmedium confidence
Die adjuvante Pharmakotherapie hat einen deutlich größeren Stellenwert als in der vorhergehenden Version der Leitlinie, da mit den Glucagon-like Peptide-1 (GLP-1)-basierten Wirkstoffen inzwischen sehr wirksame Ansätze nicht nur zur Gewichtsreduktion, sondern auch zur Besserung von Begleit- und Folgeerkrankungen vorliegen.
Why this rating
The guideline is based on evidence-based approaches.
Source
Interdisziplinäre S3-Leitlinie zur „Prävention und Therapie der Adipositas“ der Deutschen Adipositas-Gesellschaft (DAG) – Überblick über die Empfehlungen zu den Themen „Stigmatisierung“, „Diagnostik“ und „Therapie“
Martina de Zwaan et al. · Adipositas - Ursachen Folgeerkrankungen Therapie · 2025
DOI 10.1055/a-2552-3990
otherCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The S3 guideline for the prevention and treatment of obesity includes new recommendations on stigmatization, diagnostics, and therapy, incorporating areas like E-Health.Strong
- The previous version of the guideline did not include a literature review for obesity surgery due to limited resources, and it references an existing guideline for obesity surgery.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →